All Videos

Panelists discuss how managing psoriasis in children poses distinct challenges compared to adult patients.

Karan Lal, DO, and Helen T Shin, MD, discuss how diagnostic challenges in pediatric plaque psoriasis, such as its similarity to other skin conditions and potential underreporting, can complicate timely identification and appropriate management of the disease in children.

A dermatologist describes the factors that differentiate plaque psoriasis from other dermatological conditions and how they inform treatment approaches.

E. James Song, MD, FAAD, provides detailed insights on how our understanding of plaque psoriasis has evolved and the ways that has impacted treatment options and decisions.

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

Key opinion leaders examine upadacitinib's role in managing atopic dermatitis and its impact on improving patients' quality of life.

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

Karan Lal, DO, and Helen T Shin, MD, discuss how to address the psychosocial effects of plaque psoriasis on children and their families, exploring effective resources and interventions for support.

Panelists discuss how plaque psoriasis affects a significant number of children worldwide and can have substantial physical, emotional, and social impacts on young patients' quality of life and development.

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Medical experts examine the practical application of clinical study results to real-world atopic dermatitis management strategies.

Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.

An atopic dermatitis expert presents a case study of a 36-year-old male with a history of atopic dermatitis, emphasizing the limitations of over-the-counter corticosteroids and discussing more effective treatment options.

A key opinion leader in the field of dermatology examines treatment strategies and medication sequencing for atopic and hand dermatitis in a 20-year-old female patient, focusing on clinical considerations and optimal management approaches.

Jayme Heim, MSN, FNP-BC, presents a case study on managing atopic dermatitis in a 20-year-old female patient.

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.

Ted Lain, MD, MBA, FAAD discusses a case which addresses location-specific concerns and treatment challenges in vitiligo management.

Ted Lain, MD, MBA, FAAD discusses balancing vitiligo treatments with coverage challenges.

Ted Lain, MD, MBA, FAAD offers insights into navigating the emotional and clinical challenges in vitiligo management.

Chesahna Kindred, MD, discusses real-world experiences and cultural considerations associated with topical ruxolitinib for the treatment of vitiligo.

Chesahna Kindred, MD, discusses strategies for facial involvement and difficult repigmentation areas in association with advanced vitiligo care.

Chesahna Kindred, MD, discusses the psychological and insurance challenges associated with vitiligo.

Chesahna Kindred, MD, discusses the emotional impact and treatment perspectives across cultures.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.